Evercore ISI Group Maintains Outperform on C4 Therapeutics, Raises Price Target to $12

Benzinga Newsdesk www.benzinga.com Positive 92.2%

Neg 0% Neu 0% Pos 92.2%

Evercore ISI Group analyst Gavin Clark-Gartner maintains C4 Therapeutics (NASDAQ:CCCC) with a Outperform and raises the price target from $7 to $12.